Palabras clave
Hidroxicloroquina
Intervención terapéutica
Cómo citar
Copyright © | Todos los derechos reservados.
La revista posee los derechos de autor exclusivos para la publicación de este artículo en los términos de la ley brasileña 9610/98.
Reproducción parcial
El uso de partes de los textos, figuras y cuestionario del artículo es libre, siendo obligatoria la citación de los autores y revista.
Reproducción total
Está expresamente prohibido y debe ser autorizado por la revista.
Resumen
Objetivo: Analizar los tipos de alopecia autoinmune que se benefician del uso de hidroxicloroquina. Métodos: Se trata de una Revisión Integradora de Literatura, con búsquedas en las plataformas Biblioteca Nacional de Medicina (PubMed), Scientific Electronic Library Online (SciELO), Literatura Latinoamericana y del Caribe en Ciencias de la Salud (LILACS), Biblioteca Virtual en Salud (BVS) y el Portal de Revistas de la Coordinación de Perfeccionamiento de Personal de Nivel Superior (CAPES), en la que se utilizaron los Descriptores en Ciencias de la Salud (DeCS) en inglés “Hydroxychloroquine” Y “Alopecia”. Aplicando los criterios de inclusión y exclusión se seleccionaron 29 artículos que constituyeron esta investigación. Resultados: Se ha observado que la eficacia de la hidroxicloroquina (HCQ) varía entre los tipos de alopecias autoinmunes, siendo frecuentemente combinada con otras terapias, y su uso requiere monitorización. El subtipo más frecuentemente abordado en los estudios fue la alopecia frontal fibrosante, con énfasis en la estabilización de la condición, especialmente cuando se utiliza en combinación con otras terapias. Consideraciones finales: La HCQ mostró mayor eficacia en alopecias cicatriciales autoinmunes, con estabilización inflamatoria y un perfil de seguridad favorable, especialmente en uso prolongado y combinado. En la alopecia no cicatricial los resultados fueron inconsistentes, restringiendo su uso a casos refractarios.
Referencias
AKDOGAN N e ERSOY‐EVANS S. Hydroxychloroquine treatment for Alopecia Universalis: Report of six cases. Australasian Journal of Dermatology, 2021; 62(1): 83-85.
AL ABOUD M, et al. Alopecia. In: StatPearls [Internet]. StatPearls Publishing, 2024.
BARTON V, et al. Treatment of pediatric alopecia areata: A systematic review. J Am Acad Dermatol, 2022; 86(6): 1318-1334.
BATRA P, et al. Hair loss in lichen planopilaris and frontal fibrosing alopecia: not always irreversible. Skin Appendage Disorders, 2020; 6(2): 125-129.
BRETAS T, et al. Flushing episodes in the context of frontal fibrosing alopecia with facial papules. BMJ Case Reports CP, 2021; 14(8): 242017.
BROSHTILOVA V, et al. Cicatricial alopecia-a case report with a review of literature. Scripta Scientifica Medica, 2018; 50(1): 41-44.
CID PM, et al. Alopecia frontal fibrosante: estudio retrospectivo de 75 pacientes. Actas Dermo-Sifiliográficas, 2020; 111(6): 487-495.
CONTIN L, et al. Frontal Fibrosing Alopecia Coexisting with Lupus Erythematosus: Poor Response to Hydroxychloroquine. Skin Appendage Disord, 2017; 2(3-4): 162-165.
DAŃCZAK-PAZDROWSKA A e POLAŃSKA A. The place of hydroxychloroquine in modern dermatology. Dermatology Review/Przegląd Dermatologiczny, 2021; 108(3): 178-190.
SOUSA MNA, et al. Trilhando o caminho do conhecimento: o método de revisão integrativa para análise e síntese da literatura científica. Observatorio de la economía latinoamericana, 2023; 21(10): 18448-18483.
DEL TORO NP, et al. Prevalence and treatment patterns in patients with lichen planopilaris. JAMA dermatology, 2024; 160(8): 865-868.
DINA Y e AGUH C. Algorithmic approach to the treatment of frontal fibrosing alopecia: a systematic review. Journal of the American Academy of Dermatology, 2021; 85(2): 508-510.
EZZAT R, et al. Frontal Fibrosing Alopecia Part II: Etiopathogenesis and Management. Journal of the American Academy of Dermatology, 2025.
FELTRINI M, et al. Alopecia frontal fibrosante: uma revisão de literatura. Revista foco, 2025; 18(3): 7938.
FERTIG R, et al. Therapeutic options in frontal fibrosing alopecia. Expert Opinion on Orphan Drugs, 2016; 4(5): 461-468.
FERTIG R e TOSTI A. Frontal fibrosing alopecia treatment options. Intractable & rare diseases research, 2016; 5(4): 314-315.
GAMRET AC, et al. Frontal fibrosing alopecia: efficacy of treatment modalities. International Journal of Women's Health, 2019; 273-285.
GISONDI P, et al. The safety profile of hydroxychloroquine: major cutaneous and extracutaneous adverse events. Clin Exp Rheumatol, 2021; 39(5): 1099-1107.
HE X, et al. A case of neuropsychiatric systemic lupus erythematosus with hair loss as the first diagnostic symptom. Frontiers in Psychiatry, 2022; 13: 839566.
HUO R, et al. Hydroxychloroquine: A double edged sword. Molecular Medicine Reports, 2025; 31(4): 1-11.
JAMBUSAYEE J e SUDHA KM. A randomised, open label comparative study of hydroxychloroquine with betamethasone oral mini pulse in the management of patients with alopecia areata. International Journal of Basic & Clinical Pharmacology, 2021; 10(2): 187-193.
JIAN X, et al. Systemic lupus erythematosus complicated by anti-MDA5 antibody-positive juvenile dermatomyositis: A rare overlap syndrome in childhood. Rheumatology & Autoimmunity, 2025; 5(1): 71-72.
KĘPIŃSKA K, et al. Fibrosing Alopecia - a review and a practical guide for clinicians. Ann Agric Environ Med, 2022; 29(2): 169-184.
KŁOSOWICZ A, et al. Dendritic cells as predictive markers of responsiveness to hydroxychloroquine treatment in primary cicatricial alopecia patients. Dermatologic Therapy, 2020; 33(6): 14509.
LIANG KR, et al. Resolution of Discoid Lupus Alopecia With Systemic Hydroxychloroquine and Topical Pimecrolimus Combination Therapy. Cureus, 2024; 16(6): 63419.
LIPNER SR e WANG Y. Retrospective analysis of dermatologic adverse events associated with hydroxychloroquine reported to the US Food and Drug Administration. Journal of the American Academy of Dermatology, 2020; 83(5): 1527.
LYAKHOVITSKY A, et al. A case series of 46 patients with lichen planopilaris: demographics, clinical evaluation, and treatment experience. Journal of Dermatological Treatment, 2015; 26(3): 275-279.
MARDONES F e SHAPIRO J. Lichen planopilaris in a Latin American (Chilean) population: demographics, clinical profile and treatment experience. Clinical and Experimental Dermatology, 2017; 42(7): 755-759.
NAEINI FF, et al. Clinical efficacy and safety of methotrexate versus hydroxychloroquine in preventing lichen planopilaris progress: a randomized clinical trial. International Journal of Preventive Medicine, 2017; 8(1): 37.
NISSEN CV e WULF HC. Hydroxychloroquine is ineffective in treatment of alopecia totalis and extensive alopecia areata: a case series of 8 patients. JAAD Case Reports, 2016; 2(2): 117-118.
OSMAN S e TRABOULSI D. Hydroxychloroquine for granuloma annulare: A case report on secondary hair growth in alopecia universalis. SAGE Open Medical Case Reports, 2023; 11: 2050313X231152066.
ÖZCAN D, et al. Lichen planopilaris: Demographic, clinical and histopathological characteristics and treatment outcomes of 25 cases. Turkderm - Arch Turk Dermatol Venerology, 2015; 49(246): 52.
PAUDEL V, et al. Alopecia Universalis Associated with Hyperthyroidism Treated with Azathioprine and Hydroxychloroquine: A Case Report. JNMA J Nepal Med Assoc, 2021; 59(241): 935-937.
QI JI e GARZA LA. An overview of alopecias. Cold Spring Harbor perspectives in medicine, 2014; 4(3): 13615.
RAVIPATI A, et al. Use of Hydroxychloroquine in Hair Disorders. Skin appendage disorders, 2023; 9(6): 416-422.
REAGIN H, et al. Linear Cutaneous Lupus Erythematosus Following Blaschko’s Lines on the Scalp: Additional Cases and Review of the Literature. HCA Healthcare Journal of Medicine, 2022; 3(2): 51.
RYPKA K J, et al. A single-center retrospective cohort study of hydroxychloroquine-related adverse events in adults with lymphocytic cicatricial alopecia. Journal of the American Academy of Dermatology, 2025; 92(4): 932-934.
SABER M, et al. Clinical effectiveness of finasteride versus hydroxychloroquine in the treatment of frontal fibrosing alopecia: A randomized controlled trial. Journal of Cosmetic Dermatology, 2024; 23(2): 576-584.
SANTANA VVR, et al. Revisão integrativa de literatura fatores de risco para o agravamento da Covid-19 em indivíduos jovens. Enfermagem em Foco, 2020; 11(2): 37-45.
SEO H, et al. Dutasteride in the treatment of frontal fibrosing alopecia: systematic review and meta‐analysis. Journal of the European Academy of Dermatology and Venereology, 2024; 38(8): 1514-1521.
SHARMA AN, et al. Characterizing the adverse dermatologic effects of hydroxychloroquine: a systematic review. Journal of the American Academy of Dermatology, 2020; 83(2): 563-578.
STEGE H, et al. Treatment of Lichen Planopilaris and Frontal Fibrosing Alopecia: A Retrospective, Real-Life Analysis in a Tertiary Center in Germany. Journal of Clinical Medicine, 2024; 13(16): 4947.
SUCHONWANIT P, et al. Frontal fibrosing alopecia in Asians: a retrospective clinical study. International Journal of Dermatology, 2020; 59(2): 184-190.
SUGIMOTO T, et al. Successful hydroxychloroquine treatment in a patient with systemic lupus erythematosus-associated nailfold capillary abnormalities. Rheumatology Advances in Practice, 2020; 4(2).
¬SULEMAN-RAZA Y, et al. OA08 Ocrelizumab in pregnancy in a patient with juvenile onset systemic lupus erythematosus. Rheumatology Advances in Practice, 2024; 8(1): 117-118.
TAKEZAWA K, et al. Successful treatment with hydroxychloroquine for systemic lupus erythematosus with cutaneous involvement accompanied by a xanthomatous reaction. Lupus, 2020; 29(1): 79-82.
TAVAKOLPOUR S, et al. Frontal fibrosing alopecia: An update on the hypothesis of pathogenesis and treatment. International journal of women's dermatology, 2019; 5(2): 116-123.
TRÜEB RM e DIAS M. Alopecia areata: a comprehensive review of pathogenesis and management. Clinical reviews in allergy & immunology, 2018; 54: 68-87.
TRÜEB RM, et al. Cutaneous lupus erythematosus presenting as frontal fibrosing alopecia: report of 2 patients. Skin Appendage Disorders, 2017; 3(4): 205-210.
VALDEZ-ZERTUCHE J, et al. Efficacy, safety and tolerability of drugs for alopecia: a comprehensive review. Expert Opinion on Drug Metabolism & Toxicology, 2025.
WATSON VE, et al. Immune-mediated alopecias and their mechanobiological aspects. Cells & development, 2022; 170: 203793.
ZBICIAK-NYLEC M, et al. The efficacy of antimalarial drugs in the therapy of selected forms of cicatricial alopecia. Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii, 2021; 38(2): 302-309.